This is in stark contrast to two previously published studies of ATRX loss in a variety of sarcoma subtypes [20, 21], which demonstrated loss of ATRX in 1/17 (6%) and 2/47 (4%) of MPNST samples, respectively. The gene discussed is ATRX; the disease is malignant peripheral nerve sheath tumor.